Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Study of the Safety and Efficacy of Teriflunomide (HMR1726) in Multiple Sclerosis With Relapses

Trial Profile

A Phase II Study of the Safety and Efficacy of Teriflunomide (HMR1726) in Multiple Sclerosis With Relapses

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 06 May 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Teriflunomide (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Sanofi
  • Most Recent Events

    • 06 May 2019 According to a Sanofi Genzyme media release, post-hoc analysis of four clinical studies: a Phase 2 study, Phase III TEMSO, TOWER and TENERE core studies and their extensions, will be presented during the 71st annual meeting of the American Academy of Neurology (AAN) in Philadelphia, PA.
    • 12 Oct 2018 Results (n=1779) of pooled post hoc analysis of two phase 3 studies TEMSO and TOPIC and a phase 2 trial, presented at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis.
    • 12 Oct 2018 Results presented at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top